SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

VERQUVO

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since January 2021.
Why 3/10
VERQUVO is already approved and marketed with no pending regulatory decision or pivotal readout scheduled in the next ~12 months. The last major catalyst (VICTOR trial readout, August 2025) has passed. The drug is a very small contributor to Merck's $65B+ annual revenue, so even a major commercial event would have minimal impact on MRK's share price.
Actionable Insight NEUTRAL

VERQUVO has no upcoming binary catalyst. The VICTOR trial failure in August 2025 was the last major event. For Merck investors, the drug is a negligible revenue contributor and not a meaningful swing factor for the stock. Watch for any FDA action on a potential label expansion based on the VICTOR/VICTORIA pooled analysis, but no such filing has been announced. Merck's Q3 2026 earnings released today (Oct 29, 2026) showed total sales of $18.09 billion, with Verquvo buried within the 'Other' or alliance revenue line.

Price Chart

Loading chart...

Executive Summary

VERQUVO (vericiguat) is an FDA-approved heart failure drug from Merck & Co. (MRK) and co-developer Bayer. It was approved in January 2021 to reduce cardiovascular death and hospitalization risk in patients with worsening chronic heart failure with reduced ejection fraction. The drug has a novel mechanism as an sGC stimulator but has struggled commercially, generating only about $21 million in U.S. sales in the first half of 2025. A Phase 3 trial (VICTOR) in stable patients without recent worsening failed its primary endpoint in August 2025, though a pooled analysis showed broader benefit. VERQUVO is a very small part of Merck's diversified $65B+ revenue base, competing against much larger therapies like Novartis' Entresto and SGLT2 inhibitors.

How It Works

VERQUVO is a soluble guanylate cyclase (sGC) stimulator. It works by helping blood vessels relax and widen, which reduces the workload on the heart. It is taken as a once-daily oral tablet.

Trial Status

VERQUVO was approved by the FDA in January 2021 based on the positive Phase 3 VICTORIA trial in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF). A subsequent Phase 3 trial (VICTOR), read out in August 2025, tested VERQUVO in stable HFrEF patients without a recent worsening event. VICTOR failed its primary composite endpoint (cardiovascular death or heart failure hospitalization), though a pooled analysis with VICTORIA showed a significant benefit across the broader HFrEF population. The drug carries an FDA label for use after a recent hospitalization or need for IV diuretics.

The Two-Sided Case

▲ Bull Case4
VERQUVO is the first and only sGC stimulator approved for heart failure, offering a novel mechanism distinct from Entresto, SGLT2 inhibitors, and other standard therapies.
A pooled analysis of VICTOR and VICTORIA (11,155 patients) showed a significant reduction in cardiovascular death or heart failure hospitalization across the broad HFrEF population, suggesting potential for expanded use.
Adempas/Verquvo combined alliance revenue grew to $112 million in Q3 2026 from $102 million in Q3 2024, indicating steady commercial progress in Bayer's territories.
Patent protection extends to approximately 2031-2032, providing a long runway without generic competition.
▼ Bear Case4
VERQUVO is a very small product for Merck. In the first half of 2025, Merck recorded only $21 million in U.S. sales, far below the original peak sales projection of $300 million.
The Phase 3 VICTOR trial failed its primary endpoint in stable HFrEF patients, limiting the addressable population and dampening hopes for a major label expansion.
VERQUVO faces intense competition from Novartis' Entresto (a $8.6 billion market in 2026), SGLT2 inhibitors like Farxiga and Jardiance, and Bayer's own Kerendia, all of which have stronger clinical evidence and guideline recommendations.
NCE exclusivity expired in January 2025, and while patents extend to 2031-2032, the drug's modest commercial trajectory limits its value to Merck's overall business.

Upcoming Catalysts

  • No major binary catalyst is scheduled. The drug is already approved and commercializing. Future catalysts would be limited to potential label expansion data or guideline updates.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 11

Hover a chip for the title
1 merck.com2 accessdata.fda.gov3 fda.gov4 merck.com5 fiercepharma.com6 tradingview.com7 drugpatentwatch.com8 merck.com9 cnbc.com10 drugs.com11 pharmadossier.com